Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $129.43 Average PT from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $129.43.

Several equities research analysts have weighed in on the company. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Finally, Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th.

Lantheus Trading Up 0.3 %

LNTH stock opened at $97.93 on Friday. Lantheus has a 1-year low of $58.16 and a 1-year high of $126.89. The stock has a 50-day moving average price of $93.41 and a 200-day moving average price of $96.28. The firm has a market cap of $6.71 billion, a PE ratio of 16.29 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. On average, analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the 3rd quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. grew its stake in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC purchased a new position in Lantheus during the 3rd quarter worth $60,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.